Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111 panitumumab

A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope indium In 111, with potential use as an imaging agent upon single photon emission computed tomography/computed tomography (SPECT/CT). Upon administration of Indium In 111 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon SPECT/CT imaging, EGFR-expressing tumor cells can be visualized and assessed. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:111In panitumumab
111In-panitumumab
In 111-panitumumab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search